ASX Growth Companies With High Insider Ownership In July 2025
Name
Insider Ownership
Earnings Growth
Titomic (ASX:TTT)
11.2%
77.2%
Newfield Resources (ASX:NWF)
31.5%
72.1%
Image Resources (ASX:IMA)
22.3%
79.9%
Fenix Resources (ASX:FEX)
21.1%
53.4%
Echo IQ (ASX:EIQ)
18%
51.4%
Cyclopharm (ASX:CYC)
11.3%
97.8%
Brightstar Resources (ASX:BTR)
11.6%
106.7%
AVA Risk Group (ASX:AVA)
15.4%
108.2%
Alfabs Australia (ASX:AAL)
10.8%
41.3%
Adveritas (ASX:AV1)
19.9%
88.8%
Click here to see the full list of 94 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Kogan.com Ltd is an online retailer based in Australia with a market capitalization of A$384.35 million.
Operations: The company generates revenue through its operations in Australia, with A$309.36 million from Kogan Parent and A$9.96 million from Mighty Ape, as well as in New Zealand, earning A$40.02 million from Kogan Parent and A$124.88 million from Mighty Ape.
Insider Ownership: 20.8%
Kogan.com is poised for significant earnings growth, forecasted at 34.5% annually, outpacing the Australian market's 10.9%. Despite a dip in profit margins to 0.4% from last year's 1.4%, the company trades at a substantial discount of 63.4% below its estimated fair value, presenting potential value opportunities. Recent executive changes include Belinda Cleminson's appointment as Company Secretary, enhancing corporate governance with her extensive experience in listed companies.
Take a closer look at Kogan.com's potential here in our earnings growth report.
Our comprehensive valuation report raises the possibility that Kogan.com is priced lower than what may be justified by its financials.
Simply Wall St Growth Rating: ★★★★★★
Overview: Meeka Metals Limited focuses on the exploration and development of gold properties in Western Australia, with a market cap of A$422.78 million.
Operations: Meeka Metals Limited's revenue segments are currently not specified in the provided text.
Insider Ownership: 12%
Meeka Metals is set for strong growth, with earnings forecasted to rise 54.14% annually and revenue expected to grow at 56.1% per year, significantly outpacing the Australian market. Despite generating less than US$1 million in revenue (A$329K), it trades at a 28.6% discount to its estimated fair value. A recent A$60 million equity offering supports expansion efforts, while high insider ownership aligns management interests with shareholders despite no recent insider trading activity noted.
Get an in-depth perspective on Meeka Metals' performance by reading our analyst estimates report here.
Insights from our recent valuation report point to the potential undervaluation of Meeka Metals shares in the market.
Simply Wall St Growth Rating: ★★★★★☆
Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics for genetic diseases, with a market capitalization of A$755.32 million.
Operations: The company generates revenue of A$24.99 million from its activities in the discovery and development of novel RNA therapeutics for genetic diseases.
Insider Ownership: 35.9%
PYC Therapeutics is poised for growth, with earnings expected to increase by 24.3% annually and become profitable within three years, outperforming the market. Despite recent shareholder dilution, it trades at a significant discount to its estimated fair value. Insider ownership remains high, aligning management interests with shareholders. Recent developments include dosing in a Phase 1a trial of PYC-003, indicating progress in their clinical pipeline and potential future revenue catalysts despite slower revenue growth forecasts of 12.6% annually.
Unlock comprehensive insights into our analysis of PYC Therapeutics stock in this growth report.
The analysis detailed in our PYC Therapeutics valuation report hints at an inflated share price compared to its estimated value.
Take a closer look at our Fast Growing ASX Companies With High Insider Ownership list of 94 companies by clicking here.
Seeking Other Investments? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ASX:KGN ASX:MEK and ASX:PYC.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Skift
28 minutes ago
- Skift
Hyatt to Debut The Unbound Collection in Thailand
CBRE's second annual Top 10 Hotel Owners and Operators Report for Australia and New Zealand benchmarks the largest hotel groups by room counts and also introduces exclusive sentiment insights from senior executives across the sector. On the owners' side, Meriton retains the top spot with 6,211 rooms despite slowing growth and a reduced pipeline. CBRE said Millennium and Copthorne advanced one place to 7th position, expanding their portfolio to 18 hotels and 3,148 rooms. Accor remains the dominant operator, managing 65,075 rooms, more than four and a half times the next largest operator. Accor expanded its network by almost 1,700 rooms and added five hotels, bringing its total footprint to 406 properties. EVT and Meriton appear on both the Top 10 Owners and Operators lists. In terms of industry sentiment, CBRE said 82% of executives expressed a somewhat optimistic outlook for the second half of 2025 and into 2026. 64% said they plan to expand their portfolios through
Yahoo
an hour ago
- Yahoo
Santos flags delay in $18.7bn takeover bid by ADNOC-led consortium
Australia's second-largest independent gas producer, Santos, has announced a delay in the $18.7bn takeover bid by an Abu Dhabi National Oil Company (ADNOC)-led consortium, extending the exclusive due diligence period by at least one month past the initial deadline, as reported by Reuters. The consortium, which includes Abu Dhabi Development Holding Company (ADQ) and Carlyle, is said to have informed Santos that additional time is required to secure all necessary approvals for formalising the bid. The consortium's proposed offer of A$8.89 per share has been under scrutiny, with Santos shares trading below the proposed value since the announcement on 16 June. Despite the delay, ADNOC's international investment arm, XRG, stated that the consortium will continue due diligence and negotiations. The enterprise value of Santos, including net debt, would reach A$36.4bn, potentially marking the largest all-cash corporate buyout in Australian history, as per FactSet data. Rystad Energy Gas and LNG Research vice-president Kaushal Ramesh was quoted by the news agency as saying: "This was never going to be an easy transaction to pull off with the confluence of domestic energy security and national interest considerations as well as the multitude of hard to please stakeholders involved.' Regulatory approvals from Australia, Papua New Guinea and the US are essential for the deal to proceed, given Santos' asset distribution across these jurisdictions. Jamie Hannah, deputy investment director at Santos shareholder Van Eck, said: "I don't think (the delay) is going to change the overall risk to the takeover, and that is still the Foreign Investment Review Board. I think that is probably the biggest risk to the whole takeover.' Australia's gas market is under political scrutiny, with warnings of a potential gas shortfall in the eastern states by 2028. Santos' long-delayed Narrabri gas project in New South Wales is seen as a solution to this impending issue. In the previous year, Woodside and Santos were engaged in $52bn merger talks, which ultimately failed. Woodside chief executive Meg O'Neill stated Woodside's lack of interest in a rival bid. If the current bid is successful, the consortium would receive control of two Australian liquefied natural gas (LNG) operations and assets in Papua New Guinea, including the prized PNG LNG and Papua LNG projects. The two Australian LNG operations are Gladstone LNG and Darwin LNG. Santos is also progressing with its Alaskan oil project, Pikka, which is set to commence production in mid-2026. In the meantime, Santos has postponed its interim earnings report to 25 August from the initially planned 20 August. "Santos flags delay in $18.7bn takeover bid by ADNOC-led consortium" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
CSL slashes 15% of workforce and offshoots vaccine division
Australia's largest pharmaceutical company CSL will reduce its headcount by 15% and spin off its vaccine division in response to an 'unprecedented level of challenge and volatility'. CSL expects a one-off, pre-tax restructuring cost hit of $700m-$770m in the 2026 financial year. The company has conducted a series of changes across its research & development (R&D) department, operating model, and plasma network. For example, the company closed 22 underperforming plasma centres in August 2025. CSL did not disclose the areas of the company from where the 15% reduction in employee base would be initiated. As of 2024, CSL employs 32,000 people globally. The initiatives are expected to lead to savings of $500m-$550m progressively over the next three years, with the majority achieved by the end of the 2027 financial year. CSL said it would redirect the funds to 'high priority opportunities'. While most of CSL's revenue comes from its blood plasma treatments for rare illnesses, the pharma company is also one of the world's largest influenza vaccine manufacturers. It supplies more than 130 million doses of seasonal influenza doses globally each year in its Afluria, Fluad and Flucelvax brands. CSL also announced a planned spin-off of its vaccine division, known as CSL Seqirus. The company did not disclose a valuation for the demerger, which is slated to be completed in early 2026 and produce a publicly listed company in Australia, but CEO Dr Paul McKenzie said it would help 'reshape and simplify the [core] business'. Profit in the vaccine unit dipped due to reduced demand in the US – a revenue area the company hopes to address in 2026. "We firmly believe that a simplified and focused CSL is best for patients, best for our people, and best for our shareholders,' McKenzie added. The company said it would also buy back A$750m ($486.50m) of shares this financial year, partaking in a wider trend of share buybacks across the global pharma industry. Sanofi and Eli Lilly are both undertaking billion-dollar share buyback programmes. The significant restructuring, announced on CSL's 2025 financial year earnings report, eclipsed what was a positive year for the company. Net profit after tax was $3bn for the past 12 months up to June 2025, a rise of 15% on constant currencies. CSL's headcount reduction and vaccine spinoff dragged shares down 9.5%, from A$271.32 at market close on 18 August to A$245.45 at market open on 19 August. The Australian-listed company has a market cap of A$109.1bn, making it the country's fifth-largest company. In regard to impacts from tariffs, McKenzie said CSL's strategic initiatives would not be impacted due to its heavy US manufacturing presence. His statement echoed wider sentiment shared by big pharma company execs in the Q2 earnings window, many of whom expect minimal impact. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "CSL slashes 15% of workforce and offshoots vaccine division" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
